A horse has been immunized with Australia antigen (Au/SH) purified 20-fold by a procedure employing gel filtration of Cohn fraction IV derived from an Au/SHpositive human plasma pool. Hyperimmunization was initiated by the intramuscular injection of 20 ml of a mixture of equal parts of purified Au/SH and complete Freund's adjuvant. The 20-ml volume was divided into four 5-ml doses, two of which were administered on each side of the horse's neck. Booster doses of antigen alone were given as follows: 10 ml intravenously 30 days later and 5 ml intramuscularly on each of days 77 and 205. Au/SH antibody formed readily, beginning on day 17, and was demonstrated by the agar gel double-diffusion technique and the complement fixation test during the subsequent 6 months. Antihuman plasma protein antibodies were effectively removed from the horse serum by one absorption with 1 to 3 volumes of normal human plasma. Abrupt rises in anticomplementary activity observed shortly after the third and fourth antigen injections, when the horse had developed elevated and steady levels of Au/SH antibody, could possibly be due to formation of antigen-antibody complexes. After optimal conditions were determined, an Au/SH antibody reagent pool which met official requirements was prepared. It was found equally suitable for the agar gel double-diffusion, complement fixation, and counterimmunoelectrophoresis test procedures.
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Discovery of Australia antigen (Au/SH) and its association with viral hepatitis (1, 2, 10) has stimulated great interest and activity in the study of all facets of this infection (15) . In particular, in an effort to reduce the risk of post-transfusion hepatitis, it has generated considerable pressure for routine testing of all blood donations intended for transfusion, even though available techniques would detect only 25 to 30% of expected serum hepatitis carriers (14, 15) . Within a brief period, there has been a proliferation of test methods advocated for the detection of Au/SH; some are claimed to be more sensitive than others (15) . All of these methods, however, have depended primarily on an antibody found in the serum of some multiply transfused hemophilia patients.
In an attempt to make the supply of Au/SH antibody more dependable and, above all, more widely available, its preparation in a number of animal species was and continues to be investigated. Although success has been reported with small animals (6, 8, 11) , the limited yields preclude large-scale production. Initial results in goats and donkeys were encouraging, but sera from these species were not suitable for the complement fixation (CF) test (15) .
We have prepared Au/SH antibody in goats, sheep, and in one horse. Of the three, the last has provided the most useful and economic source of an antibody equally suitable for the microOuchterlony agar gel double-diffusion technique (AG), the CF test, and the counterimmunoelectrophoresis method (CEP; reference 9). The results obtained in the horse are reported here.
MATERIALS AND METHODS
Purification of Au/SH. Antigen preparations 1272-6 and 1272-17B that were used to hyperimmunize the horse were both derived from a single 14-liter pool of plasmas from human Au/SH carriers. These had been identified in a prison population studied earlier for the presence of Au/SH (5). The AG titers of individual plasmas against a reference antiserum (KK, see below) ranged from undiluted to 1:32, and the titer of the pool was 1:8.
The antigen was isolated from Cohn fraction IV of the plasma pool, since fraction IV of Au/SH-positive plasmas has been shown to contain large amounts of Au/SH (12) .
Au/SH was purified by means of gel ifitration of fraction IV on 6% agarose columns equilibrated with citrate-glycine-NaCl buffer adjusted to pH 7.5 with NaOH. The antigen was eluted with the same buffer CABASSO ET AL. just after the breakthrough peak and before Ca2-macroglobulin. The column fractions containing the antigen were concentrated by ultrafiltration.
The two purified antigen preparations used to hyperimmunize the horse had AG titers of 1:100 (preparation 1272-6) and 1:256 (preparation 1272-17B) when titrated against a house reference human antibody (serum KK).
Serological assays. (i) The AG technique as modified by Prince (10) was used, except that protamine was omitted after it was found nonessential to the reaction (5). Standard microscope slides are layered with 3.0 ml of 0.9% agarose, and a seven-well pattern is cut in the gel. The pattern consists of a center well surrounded by six peripheral wells, each 3 mm in diameter and 3 mm apart. For antigen testing, the antiserum is placed in the center well; conversely, for detecting antibody to Au/SH, the latter is placed in the center well. Test sera or plasmas are not inactivated before testing. For routine testing, each pattern includes a positive control reagent (antigen or antiserum) in the top and bottom outer wells. Incubation is in humidified chambers at room temperature (22 to 25 C). Generally, precipitin lines are recorded after 1 or 2 days.
(ii) The CF test was performed as described earlier (5) . Briefly, 0.1 ml each of antigen, antibody, hemolysin, and sheep cell suspension and 0.2 ml of complement containing 2 exact units are used. Complement titers are determined in the presence of 2 to 4 units of antigen when the antibody is titrated or in the presence of 4 units of antibody when the antigen is titrated. All sera and plasmas, whether absorbed or not, are inactivated at 56 C for 30 min before testing. Antigen, antibody, and complement mixtures are incubated overnight at 4 C. After addition of sensitized sheep erythrocytes, the mixtures are further incubated in a water bath at 37 C until the complement and hemolysin controls are completely clear (10 to 20 min). Hemolysis not greater than 2+ is recorded as the titer end point.
(iii) The CEP assay was based on the method of Pesendorfer et al. (9) , as modified by Gocke Reference antigens and antisera. Reference preparations used in testing and standardization of the horse serum samples and antibody pools were as follows.
(i) Our house reference Au/SH consisted of a human plasma (790416) selected from among several carriers for suitability in both the AG and CF tests: its AG titer against reference KK antibody was 1: 32, and its CF titer against reference antiserum CL in repeated tests varied in the narrow range of 1:512 to 1:1,024. This house reference is stored at -20 C and has been used for almost 2 years with no apparent change in titer or specificity.
Provisional or interim reference antigens were also received from the Division of Biologics Standards (ii) Three Au/SH antibody-positive sera have served as house references for the past 2 years: these are KK, CL, and DF. All three are from hemophilia patients. KK is anticomplementary and is therefore used mainly in the AG test (AG titer 1:4). CL and DF are not anticomplementary (AC). CL is reserved for the CF test (CF titer 1: 16), whereas DF is used in CEP tests (AG titer, 1: 8; CF titer, 1: 64).
Interim reference antisera were also received from the DBS and RRB. The DBS preparation is of human origin (DBS-RS, human), whereas that from the RRB is from immunized guinea pigs (RRB-RS, GP).
(iii) Identities of house reference antigen and antisera were first established by testing against reference reagents kindly provided by A. M. Prince, New York Blood Center, New York, N.Y., and by A. G. Redeker, Los Angeles County-University of Southern California Medical Center, Los Angeles.
Identity of house reference antigen 790416 was confirmed by replicate testing by the AG procedure against DBS-RS, human and RRB-RS, GP. In every instance, unequivocal lines of identity were obtained with antigens DBS 4+, DBS 2+, and RRB-V801-001-027 and not with DBS-Neg.
Similarly, identities of our house reference antisera KK, CL, and DF were confirmed by obtaining lines of identity between them and DBS-RS, human and RRB-RS, GP.
RESULTS
Hyperimmunization and bleeding schedules of the horse. The horse used in this study was a 12-year-old gelding quarter horse in good health, weighing about 500 kg (1,000 lb). Its hyperimmunization with purified Au/SH proceeded as follows.
Immediately before the initial injection, a 2-liter volume of blood was drawn to provide a preimmunization serum sample for future testing. The initial injection consisted of 10 ml of prepara- intravenous route for further injections of purified Au/SH. A 5-ml booster of preparation 1272-17B was injected 37 days after the intravenous dose, and another 5-ml injection of the same antigen was given 128 days later or 205 days after the initial inoculation. There were no untoward reactions, and no further emergency treatment was required.
The bleeding schedule of the horse over a period of 223 days is as indicated in Figure 1 . Beginning 10 days after the initial four injections, a 20-ml blood sample was taken weekly for 6 weeks. When the samples indicated satisfactory response to Au/SH stimulation, 6-liter volumes of blood were aseptically withdrawn at weekly intervals. The serum was separated, clarified by centrifugation, and stored at 20 C without further processing. Small samples were retained from each 6-liter bleeding for testing, as described below.
Testing of weekly horse serum samples by AG and CF. Samples of serum were initially tested by AG against antigen 790416 by using an "in-well" absorption technique (8) . In this procedure, the test serum is introduced into the well in which normal human plasma has previously been placed. In this manner, absorption of antihuman plasma protein antibodies present in the horse serum would take place at the periphery of the well, allowing the Au/SH antibody to migrate further. In later tests, blood samples were absorbed with human plasma shown to be free of Au/SH and anticomplementary activity. The samples were tested individually as they became available and later retitrated in a single test by AG, with antigen 790416. Two to four units of this antigen was also used in titrations of the absorbed samples by CF, at which time the sera were also checked for anticomplementary activity. Results of the simultaneous tests are presented in Fig. 1 . Although absorption of the samples resulted in their dilution by a factor of two or three in most instances, titers are expressed in terms of the dilutions of the absorbed sera and dilution due to absorption is ignored. The earliest positive AG titer was on the 17-day sample. By the 30th day, when the intravenous booster was administered, the titer had reached the level of 1:16. It was 1:32 1 week later and, with few exceptions, remained at that level until day 153. Decrease in the AG titer to 1:16 during the subsequent 5 weeks may have been more apparent than real, since it again was 1:32 on day 202, 3 days before the last booster. It did not increase beyond 1:32 during the 2 weeks that followed the latter.
The CF antibody also first became measurable on the 17-day sample (titer 1:64). Its titer rose to 1:512 1 week after the 30-day booster and then levelled off at 1:128 until day 70, with one exception on day 48 (titer 1:256). On day 77, when the first intramuscular booster was given, the titer had decreased to 1:64. It cannot be ascertained from the data whether omission of the 77-day booster would have resulted in gradually decreasing titers. In any case, the titer rose abruptly to 1:512 on the week after the booster, and decreased stepwise to 1:16 to 1:32 over the subsequent 120 days. The same abrupt return to 1: 512 was noted 11 days after the 205-day intramuscular booster, followed again by a gradual decrease.
Development of anticomplementary activity seemed to be influenced by booster injections of antigen. Starting at undetectable levels on days 0 and 10, anticomplementary activity was first detected on day 17 (titer 1:4) when the Au/SH antibody first appeared. Its titer began to decrease on day 24, after a peak titer of 1: 8, but rebounded to 1:16 after the first booster injection. It began to decline once again after day 48, reaching a level of 1:4 between days 62 and 77. As was the case with the CF titer, it also rose abruptly to 1:256 1 week after the second booster. Thereafter, it gradually returned to undetectable levels on day 160 and remained undetected until the 205-day booster. Then, another rapid rise to a titer of 1:128 occurred and started to decrease again on day 216.
Preparation and standardization of equine Au/ SH antibody reagent. The blood sample obtained 55 days after the start of hyperimmunization of the horse was selected for preparation of a pool of Au/SH antibody reagent. The choice was made on the basis of an elevated CF titer (1 :128) and a relatively low anticomplementary titer (1:8) .
With a small sample of serum from this bleeding, it was determined that 3 volumes of normal human plasma was required to absorb completely antibodies against human plasma proteins in the horse serum. Consequently, a 1,400-ml portion of the pool was absorbed with 4,200 ml of human plasma. The latter was a pool of equal volumes of five normal plasmas. After 48 hr at 4 C, the precipitate that formed was removed by centrifugation at 2,000 rev/min for 10 min, and the supernatant fluid was stored at -20C. Three days later, the fluid was thawed and passed through sterile cotton gauze to remove the small amount of fibrinogen which had aggregated. The resulting clarified preparation was designated 1250-132.
A On the basis of these AG and CF results, 4,000 ml of 1250-132 was diluted 1:4 by mixing with 12,000 ml of saline containing 3.2 g of sodium azide as preservative. The resulting preparation, designated 1250-136, represented the final Au/SH antibody reagent. It was dispensed into smaller volume containers and was stored at -20 C while its standardization (or potency testing) was being carried out in several tests, including AG, CF, and CEP.
In a first AG test, 1250-136 was tested against An abrupt rise of anticomplementary activity of the horse serum followed the third and fourth antigen injections, at the time when elevated and steady Au/SH antibody levels had developed. It is possible that this rise was due to sudden formation in the horse of large quantities of antigenantibody complexes which removed complement from circulation. This hypothesis conforms to Shulman and Barker's explanation of the nature of anticomplementary activity in sera from hemophilia patients (13), a suggestion which received recent confirmation by Millman et al. (7), who reported direct evidence of the presence of antigen-antibody complexes in the serum of two Au/SH-positive patients, and by Gocke et al. (4) , who demonstrated the presence of complexes of Au/SH, Au/SH antibody, and complement in the sera of patients with typical polyarteritis syndromes and mild hepatic damage.
